CADILA HEALTHCARE LTD. - 532321 - Shareholding for the Period Ended June 30, 2019
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here06-07-2019
06-07-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Misoprostol Tablets03-07-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Misoprostol Tablets03-07-2019
CADILA HEALTHCARE LTD. - 532321 - Closure of Trading Window
Closure of Trading Window for Designated Persons and their immediate relatives.29-06-2019
CADILA HEALTHCARE LTD. - 532321 - Related Party Transactions Under Regulation 23(9) Of The SEBI LODR, 2015
Related Party Transactions under Regulation 23(9) of the SEBI LODR, 201527-06-2019
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate26-06-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Announces Completion of Enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH17-06-2019
CADILA HEALTHCARE LTD. - 532321 - Notification
Company''s formulations manufacturing facility located at SEZ Ahmedabad has received an Establishment Inspection Report (EIR).17-06-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached the updated Investor Presentation.17-06-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus' Nesher Pharmaceuticals receives final approval from the USFDA for Omega-3-Acid Ethyl Esters Capsules15-06-2019